Please assess the completion status of the following clinical trial:

Trial Title: Low-Dose Alteplase to Treat Blood Clots in Deep Leg Veins

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
INCLUSION CRITERIA~* Only adult patients (18 years old or older) are included.~* Patients must have thrombosis documented by ultrasound or venography to involve the deep veins of the pelvis and/or a lower extremity proximal to the calf veins, i.e., the popliteal vein or above.~* The thrombosis must be the patient's first DVT.~* The thrombosis must have been symptomatic for no more than 14 days.~* Patients must be able to give informed consent and be able to follow the prescribed anticoagulation regimen.~* Patients on concurrent NIH protocols will be eligible as well as patients from the community and the rest of the U.S. who are not already on NIH protocols.~EXCLUSION CRITERIA~* Pregnant patients are not eligible, although postpartum mothers over 10 days from delivery are eligible if they refrain from breast feeding their infants for 24 hours after each study with x-ray contrast material.~* Serum creatinine greater than than 2 mg/dL.~* Any current bleeding diathesis not attributable to heparin or warfarin. Fibrinogen less than 150 mg/dL. Any patient with a prothrombin time (PTT) greater than 15 s, an activated partial thromboplastin time (aPTT) greater than 35 s, or a platelet count less than 100,000/microliter must be evaluated by the Hematology Service for a coagulopathy before being included.~* Within the previous 10 days: major surgery or trauma, puncture of a noncompressible vessel, organ biopsy, or cardiopulmonary resuscitation.~* Within the previous 2 months: cerebrovascular infarction or hemorrhage, or intracranial or intraspinal surgery or trauma.~* Within the previous 6 months: major internal bleeding.~* Active intracranial disease (aneurysm, vascular malformation, neoplasm).~* Life expectancy less than 6 months.~* Patients with hemoglobin concentration less than 9g/dL will not participate in the pharmacokinetic portion of the protocol.~* Uncontrolled systolic blood pressure greater than 180 mm Hg or diastolic greater than 100 mm Hg.~* Atrial fibrillation, unless a cardiac echocardiogram excludes the presence of intracardiac thrombus.~* Known right-to-left intracardiac shunt.~* Pericarditis, infective endocarditis.~* History of heparin-induced thrombocytopenia within 6 months or the presence of persistent anti-heparin antibodies by ELISA.~* History of anaphylactic reactions to x-ray contrast media.~* Known retinopathy unless cleared by an ophthalmologist at NIH.Evidence of uncontrolled congestive heart failure or a history of diabetes mellitus.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Alteplase (r-tPA) (Type: EXPERIMENTAL): Patients with DVT of lower extremity will receive up to 4 treatments low dose (\<10 mg/day) intraclot injections of alteplase. Intention is to evaluate safety and efficacy of this treatment, and durability of outcomes (for 6 months)in 25 patients.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete